Market News AIOpen the app

BioMarin is teaming up with AstraZeneca, Novo Nordisk, and Novartis to improve how RNA medicines are made.

DealRead the original at myscience.uk
Neutral

BioMarin joined a group seeking to scale enzyme-based production of therapeutic oligonucleotides and cut waste and costs. No company-specific savings, sales, or products are reported, so its outlook is unchanged.

BMRN · BioMarin Pharmaceutical Inc.

AI read · Neutral

The AI's read

The work could make RNA-medicine production cheaper and easier to expand. The story reports goals, not completed changes, and gives no BioMarin product, sales, or cost results. Its business outlook therefore remains unchanged.

AZN · AstraZeneca

AI read · Neutral

The connection

AstraZeneca joined the production collaboration, which aims to cut waste and costs. The story reports no company-specific savings, sales, or product changes, so its outlook is unchanged.

NVO · Novo Nordisk

AI read · Neutral

The connection

Novo Nordisk joined the production collaboration, which aims to cut waste and costs. The story reports no company-specific savings, sales, or product changes, so its outlook is unchanged.

NVS · Novartis

AI read · Neutral

The connection

Novartis joined the production collaboration, which aims to cut waste and costs. The story reports no company-specific savings, sales, or product changes, so its outlook is unchanged.

Get alerts for BMRN

Follow BioMarin Pharmaceutical Inc. (BMRN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BMRN
Free on the App Store and Google Play, or on the web.